Funded Projects › HORIZON
APPEAL · Antivirus Pandemic Preparedness EuropeAn pLatform
Developing new antiviral treatment against viruses and particularly high-priority emerging and re-emerging viruses as listed by the WHO, remains crucial as, among other aspects, the viruses evolve under selection. Broad spectrum host-directed antiviral drugs (HDA) are promising therapeutic options, however the robust identification of relevant host factors by genome-wide knockout screens is challenging due to low consistency in the resulting hits. Our project aims to (1) establish a computational and experimental pipeline to identify and validate an antiviral for these viruses, and (2) identify at least one broad spectrum antiviral drug against potential emerging and re-emerging viruses as listed by the WHO. To address these, we will implement a drug selection pipeline following several strategies: We will employ (i) machine learning, based on data from knockout screens, proteomics, protein interaction, transcriptomics of infected cells with pandemic-related viruses, Genome-Wide Association Studies, and generic gene descriptors, (ii) High Density Cell Arrays, which provide much more detailed readouts compared to state of the art pooled knockout screens, (iii) primary cell cultures obtained from a diverse array of human tissues, as they are more appropriate to study the host cell physiology during infection, compared to cancer cell lines, and (iv) use the pipeline to identify host restriction factors, which, when activated, challenge the virus; followed by innovative drug development and delivery based on small activating RNA. The pipeline comprises an Expedited Arm for which broad spectrum antiviral drugs for repurposing will be selected followed by in vitro and in vivo efficacy testing, and a clinical trial as a proof of concept. The elaborated Arm includes all strategies (i)-(iv) and will provide a sustainable pandemic preparedness pipeline ready-to-operate to identify the appropriate treatment against the emerging virus at the early time of a new outbreak.
Consortium · 15 organisations
UNIVERSITATSKLINIKUM JENA
DE · €1,714,516
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
FR · €54,375
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
UK
CONSULTECH TECHNOLOGIEBERATUNG GMBH
DE · €429,375
UNIVERSITATSMEDIZIN GREIFSWALD KORPERSCHAFT DES OFFENTLICHEN RECHTS
DE · €337,589
MATTEK IN VITRO LIFE SCIENCE LABORATORIES SRO
SK · €663,750
TECHNISCHE UNIVERSITAET MUENCHEN
DE · €554,146
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
DE · €797,125
EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS
BE · €532,896
PHARMAI DISCOVERY GMBH
DE · €226,993
INSTITUT PASTEUR
FR · €1,104,730
JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
DE · €69,825
ACONDICIONAMIENTO TARRASENSE ASSOCIACION
ES · €363,438
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
NL
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
FR · €716,915
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.